FDA clears Risperdal Consta for bipolar I disorder

05/18/2009 | Forbes · Reuters

Janssen received FDA approval to use Risperdal Consta, a long-acting version of bipolar disorder drug Risperdal, in people with bipolar I disorder. The clearance allows the unit of Ortho-McNeil-Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to market the product as either a standalone treatment or a combination therapy with lithium or valproate.

View Full Article in:

Forbes · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC